SG11201807652SA - Derivatives of amanita toxins and their conjugation to a cell binding molecule - Google Patents

Derivatives of amanita toxins and their conjugation to a cell binding molecule

Info

Publication number
SG11201807652SA
SG11201807652SA SG11201807652SA SG11201807652SA SG11201807652SA SG 11201807652S A SG11201807652S A SG 11201807652SA SG 11201807652S A SG11201807652S A SG 11201807652SA SG 11201807652S A SG11201807652S A SG 11201807652SA SG 11201807652S A SG11201807652S A SG 11201807652SA
Authority
SG
Singapore
Prior art keywords
hangzhou
heda
zhejiang
street
room
Prior art date
Application number
SG11201807652SA
Inventor
Robert Yongxin Zhao
Qingliang Yang
Yuanyuan Huang
Shun Gai
Hangbo Ye
Chengyu Yang
Huihui Guo
Xiaomai Zhou
Hongsheng Xie
Qianqian Tong
Minjun Cao
Linyao Zhao
Junxiang Jia
Wenjun Li
Xiaotao Zuo
Chen Lin
Yifang Xu
Zixiang Guo
Original Assignee
Hangzhou Dac Biotech Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hangzhou Dac Biotech Co Ltd filed Critical Hangzhou Dac Biotech Co Ltd
Publication of SG11201807652SA publication Critical patent/SG11201807652SA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64—Cyclic peptides containing only normal peptide links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6415—Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2017/046658 Al 23 March 2017 (23.03.2017) WIPO I PCT (51) International Patent Classification: A61K 47/50 (2017.01) A61P 35/00 (2006.01) CO7K 7/64 (2006.01) (21) International Application Number: PCT/IB2016/052246 (22) International Filing Date: 20 April 2016 (20.04.2016) (25) Filing Language: English (26) Publication Language: English (71) Applicant: HANGZHOU DAC BIOTECH CO, LTD [CN/CN]; Building 12, Zhongzi Technology Park, No. 260 Sixth Street, Heda, Hangzhou City, Zhejiang 310018 (CN). (72) Inventors: ZHAO, Robert Yongxin; Room B2005, Build- ing 2, No. 452 Sixth Street, Heda, Hangzhou, Zhejiang 310018 (CN). YANG, Qingliang; Room B2006, Building 2, No. 452 Sixth Street, Heda, Hangzhou, Zhejiang 310018 (CN). HUANG, Yuanyuan; Room B2006, Building 2, No. 452 Sixth Street, Heda, Hangzhou, Zhejiang 310018 (CN). GAL Shun; Room B2003, Building 2, No. 452 Sixth Street, Heda, Hangzhou, Zhejiang 310018 (CN). YE, Hangbo; Room B2004, Building 2, No. 452 Sixth Street, Heda, Hangzhou, Zhejiang 310018 (CN). YANG, Chengyu; Room B2009, Building 2, No. 452 Sixth Street, Heda, Hangzhou, Zhejiang 310018 (CN). GUO, Huihui; Room B2002, Building 2, No. 452 Sixth Street, Heda, Hangzhou, Zhejiang 310018 (CN). ZHOU, Xiaomai; Room B2005, Building 2, No. 452 Sixth Street, Heda, Hangzhou, Zhejiang 310018 (CN). XIE, Hongsheng; Room B2006, Building 2, No. 452 Sixth Street, Heda, Hangzhou, Zhejiang 310018 (CN). TONG, Qianqian; Room B2011, Building 2, No. 452 Sixth Street, Heda, Hangzhou, Zhejiang 310018 (CN). CAO, Minjun; Room B2002, Building 2, No. 452 Sixth Street, Heda, Hangzhou, Zhejiang 310018 (CN). ZHAO, Linyao; Room B2005, Building 2, Room B2007, Building 2, No. 452 Sixth Street, Heda Hangzhou, Zhejiang 310018 (CN). JIA, Junxiang; Room B2015, Building 2, No. 452 Sixth Street, Heda, Hangzhou, Zhejiang 310018 (CN). LI, Wenjun; Room B2005, Building 2, No. 452 Sixth Street, Heda, Hangzhou, Zhejiang 310018 (CN). ZUO, Xiaotao; Room B2008, Building 2, No. 452 Sixth Street, Heda, Hangzhou, Zhejiang 310018 (CN). LIN, Chen; Room B2012, Build- ing 2, No. 452 Sixth Street, Heda, Hangzhou, Zhejiang 310018 (CN). XU, Yifang; Room B2008, Building 2, No. 452 Sixth Street, Heda, Hangzhou, Zhejiang 310018 (CN). GUO, Zixiang; Room B2013, Building 2, No. 452 Sixth Street, Heda, Hangzhou, Zhejiang 310018 (CN). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, [Continued on next page] = (54) Title: DERIVATIVES OF AMANITA TOXINS AND THEIR CONJUGATION TO A CELL BINDING MOLECULE Q (a) (57) : Derivatives of Amernita toxins of Formula (I), wherein, formula (a) R 1, R 2, R3, R 4, R s, R 6, R7, R 8, R 9, R io , X, L, m, n and Q are defined herein. The preparation of the derivatives. The therapeutic use of the derivatives in the targeted treatment of cancers, autoimmune disorders, and infectious diseases. 111111111111110111011111111111010111110011111111111111111111111111110111111111110111111 W O 20 17 /0 4665 8 Al WO 2017/046658 Al MIDEDIMOM010101g010111110011INIMIMMINVOIMIE SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Declarations under Rule 4.17: as to the identity of the inventor (Rule 4.17(1)) as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(11)) of inventorship (Rule 4.17(iv)) Published: — with international search report (Art. 21(3)) before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h)) upon request of the applicant, before the expiration of the time limit referred to in Article 21(2)(a)
SG11201807652SA 2016-04-20 2016-04-20 Derivatives of amanita toxins and their conjugation to a cell binding molecule SG11201807652SA (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/IB2016/052246 WO2017046658A1 (en) 2016-04-20 2016-04-20 Derivatives of amanita toxins and their conjugation to a cell binding molecule

Publications (1)

Publication Number Publication Date
SG11201807652SA true SG11201807652SA (en) 2018-10-30

Family

ID=58288166

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201807652SA SG11201807652SA (en) 2016-04-20 2016-04-20 Derivatives of amanita toxins and their conjugation to a cell binding molecule

Country Status (15)

Country Link
US (1) US10836796B2 (en)
EP (1) EP3445401A4 (en)
JP (2) JP7295640B2 (en)
KR (1) KR102295190B1 (en)
CN (2) CN109689107B (en)
AU (1) AU2016322708B2 (en)
BR (1) BR112018071465A2 (en)
CA (1) CA3016172C (en)
MX (1) MX2018012803A (en)
MY (1) MY197235A (en)
NZ (1) NZ744936A (en)
PH (1) PH12018501777A1 (en)
SG (1) SG11201807652SA (en)
WO (1) WO2017046658A1 (en)
ZA (1) ZA201807613B (en)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11129910B2 (en) 2016-02-04 2021-09-28 Hangzhou Dac Biotech Co., Ltd. Specific conjugation linkers, specific immunoconjugates thereof, methods of making and uses such conjugates thereof
KR20230082055A (en) 2016-06-17 2023-06-08 마젠타 테라퓨틱스 인코포레이티드 Compositions and methods for the depletion of cells
EP3888691A1 (en) * 2016-11-14 2021-10-06 Hangzhou Dac Biotech Co., Ltd. Conjugation linkers, cell binding molecule-drug conjugates containing the likers, methods of making and uses such conjugates with the linkers
TWI825007B (en) 2017-01-20 2023-12-11 德商海德堡醫藥研究有限責任公司 Compositions and methods for the depletion of cd137+ cells
US10093731B2 (en) 2017-02-24 2018-10-09 Kindred Biosciences, Inc. Anti-IL31 antibodies for veterinary use
CA3058712C (en) * 2017-04-06 2023-04-18 Hangzhou Dac Biotech Co., Ltd Conjugation of a cytotoxic drug with bis-linkage
CN110997676B (en) * 2017-08-07 2022-12-20 海德堡医药研究有限责任公司 Novel method for synthesizing amanitine
WO2019034175A1 (en) * 2017-08-18 2019-02-21 四川百利药业有限责任公司 Non-natural amatoxin-type antibody conjugate
KR20190043031A (en) * 2017-10-17 2019-04-25 한국화학연구원 Amatoxin derivatives and methods for their preparation
BR112020008228A2 (en) 2017-10-24 2020-10-13 Magenta Therapeutics, Inc. compositions and methods for the depletion of cd117+ cells
TW201922782A (en) 2017-10-24 2019-06-16 美商麥珍塔治療學股份有限公司 Compositions and methods for the depletion of CD117+ cells
CA3085634C (en) * 2017-12-31 2023-11-14 Hangzhou Dac Biotech Co., Ltd A conjugate of a tubulysin analog with branched linkers
CN109096128B (en) * 2018-01-12 2021-03-09 江苏金斯瑞生物科技有限公司 Preparation method of aminopolyethylene glycol propionic acid
WO2020125546A1 (en) * 2018-12-17 2020-06-25 荣昌生物制药（烟台）有限公司 Connector for use in antibody medicament conjugate and applications of connector
CA3128264A1 (en) * 2019-01-31 2020-08-06 Hangzhou Dac Biotech Co., Ltd A conjugate of an amanita toxin with branched linkers
EP3958908A1 (en) 2019-04-24 2022-03-02 Heidelberg Pharma Research GmbH Amatoxin antibody-drug conjugates and uses thereof
KR102092817B1 (en) * 2019-08-22 2020-03-24 한국화학연구원 Amatoxin derivatives and methods for their preparation
TWI710488B (en) 2019-09-18 2020-11-21 亞慶股份有限公司 Self-driving-brake-and-manual-driving-brake connecting assembly for golf cart braking system
AR120218A1 (en) * 2019-10-15 2022-02-02 Heidelberg Pharma Res Gmbh AMATOXIN AND B LYMPHOCYTE SPECIFIC ANTIBODY CONJUGATES
US20230039142A1 (en) * 2019-12-16 2023-02-09 Heidelberg Pharma Research Gmbh Synthesis of amanin and its derivatives
CN111233949A (en) * 2020-02-10 2020-06-05 天津科技大学 Ganglioside GM3 and/or its analogue, synthetic method and application
WO2021255217A1 (en) * 2020-06-19 2021-12-23 Heidelberg Pharma Research Gmbh Amatoxin and amatoxin conjugates for use in inhibition of rna virus replication
CN116284224B (en) * 2023-05-12 2023-07-25 中国农业大学 Cyclic peptide combined with Claudin18.2 and application thereof

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001270863A (en) * 2000-03-23 2001-10-02 Mitsui Chemicals Inc Method for producing 6-substituted indole derivative
PL3192529T3 (en) * 2009-04-08 2020-08-24 Heinz Faulstich Amatoxin-armed therapeutic cell surface binding components designed for tumour therapy
ES2402254T3 (en) 2010-09-30 2013-04-30 Heidelberg Pharma Ag Amatoxin conjugates with improved linkers
EP3666289A1 (en) * 2011-02-15 2020-06-17 ImmunoGen, Inc. Cytotoxic benzodiazepine derivatives
EP2497499A1 (en) 2011-03-10 2012-09-12 Heidelberg Pharma GmbH Amatoxin-conjugates with improved linkages
WO2014043403A1 (en) * 2012-09-12 2014-03-20 Agensys, Inc. Amatoxin derivatives and cell-permeable conjugates thereof as inhibitors of rna polymerase
EP3041846B1 (en) * 2013-09-02 2018-11-07 Hangzhou Dac Biotech Co., Ltd Novel cytotoxic agents for conjugation of drugs to cell binding molecule
EP3319936A4 (en) * 2015-07-12 2019-02-06 Suzhou M-conj Biotech Co., Ltd. Bridge linkers for conjugation of cell-binding molecules
JP6817288B2 (en) * 2015-08-10 2021-01-20 ハンジョウ ディーエーシー バイオテック シーオー．，エルティディ．Ｈａｎｇｚｈｏｕ Ｄａｃ Ｂｉｏｔｅｃｈ Ｃｏ．，Ｌｔｄ． Its use in novel conjugates and specific conjugation of biomolecules with drugs
US11129910B2 (en) 2016-02-04 2021-09-28 Hangzhou Dac Biotech Co., Ltd. Specific conjugation linkers, specific immunoconjugates thereof, methods of making and uses such conjugates thereof

Also Published As

Publication number Publication date
AU2016322708A1 (en) 2018-08-23
NZ744936A (en) 2022-01-28
JP2023051977A (en) 2023-04-11
JP7295640B2 (en) 2023-06-21
MX2018012803A (en) 2019-06-24
CA3016172C (en) 2024-03-12
AU2016322708B2 (en) 2020-08-20
ZA201807613B (en) 2022-02-23
CN109689107A (en) 2019-04-26
WO2017046658A1 (en) 2017-03-23
US20200079820A1 (en) 2020-03-12
MY197235A (en) 2023-06-07
US10836796B2 (en) 2020-11-17
CA3016172A1 (en) 2017-03-23
EP3445401A4 (en) 2019-11-20
KR20180125154A (en) 2018-11-22
KR102295190B1 (en) 2021-08-30
BR112018071465A2 (en) 2019-02-05
CN115181164A (en) 2022-10-14
CN109689107B (en) 2022-08-16
PH12018501777A1 (en) 2019-05-15
EP3445401A1 (en) 2019-02-27
JP2019515907A (en) 2019-06-13

Similar Documents

Publication Publication Date Title
SG11201807652SA (en) Derivatives of amanita toxins and their conjugation to a cell binding molecule
SG11201908721TA (en) Conjugation of a cytotoxic drug with bis-linkage
SG11201804170RA (en) Polycyclic tlr7/8 antagonists and use thereof in the treatment of immune disorders
SG11201908330PA (en) Farnesoid x receptor agonists and uses thereof
SG11201901390TA (en) Tetracycline compounds and methods of treatment
SG11201900163PA (en) Macrocycle kinase inhibitors
SG11201906763RA (en) Pyrrolo [1,2-b] pyridazine derivatives
SG11201804915RA (en) Methods for treating huntington's disease
SG11201906386XA (en) Combination therapy involving diaryl macrocyclic compounds
SG11201903287PA (en) Anti-respiratory syncytial virus antibodies, and methods of their generation and use
SG11201810965YA (en) 1h-pyrazolo[4,3-b]pyridines as pde1 inhibitors
SG11201906163TA (en) Nucleotide hemi-sulfate salt for the treatment of hepatitis c virus
SG11201901374WA (en) Antibiotic compounds
SG11201901457TA (en) 2'-substituted-n6-substituted purine nucleotides for rna virus treatment
SG11201906222WA (en) Jak1 selective inhibitors
SG11201805149XA (en) Compositions comprising 15-hepe and methods of using the same
SG11201906417RA (en) 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives as magl inhibitors
SG11201805001UA (en) Method of treating influenza a
SG11201903061YA (en) Combination treatments comprising administration of imidazopyrazinones
SG11201901063SA (en) Therapeutic agents for neurodegenerative diseases
SG11201901048VA (en) Pharmaceutical compositions and uses directed to lysosomal storage disorders
SG11201809561WA (en) 9-aminomethyl minocycline compounds and methods of use thereof in urinary tract infection (uti) treatment
SG11201909841RA (en) Antitumoral compounds
SG11201809534UA (en) Methods of treating autoimmune disease using allogeneic t cells
SG11201806880QA (en) Communicating with two or more slaves